Quick Answer: Singapore biomedical startups are expanding into China to tap its patient pools, hospital networks and manufacturing capacity. Lion TCR reports cutting development time by roughly half, and BetaLife estimates a small first-in-human cell therapy study could cost 20 to 50 percent less than in Singapore. The catch is China's shifting rules, including State Council Decree No. 818.
Singapore is a small market. Its biomedical founders know that a therapy built for 6 million people can struggle to prove itself at scale, and that trials often run slowly when recruitment is the bottleneck. So a growing number of startups are looking north. As CNA reported in November 2026, companies working on cancer and diabetes are using China's scale to move faster, but they're also learning that speed comes with regulatory homework.
China's Patient Pool Is the Obvious Draw
Start with the numbers. China has about 148 million adults living with diabetes, roughly a quarter of the world's adult diabetes population, according to 2024 estimates from the International Diabetes Federation. For any company testing a chronic disease therapy, that makes patient recruitment a very different problem.
Recruitment is where many early-stage programs stall. A trial needs eligible patients, willing hospitals, and enough time to observe outcomes. A larger pool doesn't guarantee faster enrolment, but it shortens the search, and that matters when your runway is measured in months.
Here's the part most coverage skips: patient volume only helps if you can reach those patients through credible clinical sites. That's why the hospital networks and the manufacturing base get as much attention from founders as the headcount does.
How Lion TCR Cut Development Time by Half
Lion TCR is the clearest example in the source. The company is a spin-off from Singapore's Agency for Science, Technology and Research (A*STAR). It ran its first clinical trials at Singapore General Hospital before setting up in China. Its method reprograms a patient's own immune cells to recognise and attack tumours, and it targets liver cancer linked to hepatitis B, a disease that's common in China and parts of Asia.
The company now runs a facility at the China-Singapore Guangzhou Knowledge City. Its CEO, Peng Xiaoming, says the move shortened the distance between research, clinical needs and manufacturers. He describes collaborations with local hospitals for clinical work and with research institutions for next-generation products. The company claims this has cut development time by roughly half.
Treat that figure as a company claim, not an independent benchmark. It's still useful, because it points to where the savings come from: fewer handoffs, shorter trips between bench and bedside, and manufacturing close to the lab.
Lion TCR is also working on an "off-the-shelf" version of its cell therapy. In general terms, off-the-shelf (allogeneic) approaches use cells from donors rather than each patient's own cells, so they can be made in advance and potentially at lower cost. The source says this version could be manufactured in different countries. That's the part to watch, because manufacturing a cell therapy across borders brings its own quality-control and regulatory requirements.
BetaLife and the Cost Case for Cell Therapy Trials
BetaLife, another A*STAR spin-off, is developing stem cell therapies meant to replace cells damaged by diabetes. Its co-founder and director, Novanne Seah, says China is central to the company's Asia and global strategy. She points to the country's large hospital manufacturing capacity, a fast-growing cell therapy ecosystem, and a gradual opening of parts of biotechnology to foreign participation.
The company has partnered with the First Affiliated Hospital of Xiamen University. In July it opened a research and manufacturing lab in Xiamen, ahead of first-in-human clinical trials. Tests and patient recruitment are already underway.
The cost figure is the one founders will quote most. Seah estimates that a small-scale first-in-human cell therapy study in China could cost 20 to 50 percent less than an equivalent programme in Singapore. She also says regulatory and site preparation could be shortened by several weeks to a few months, depending on the hospital and study design.
Again, these are estimates from a company with a stake in the outcome. They depend heavily on study design, site selection, and local labour and manufacturing costs. Use them as a starting hypothesis for your own budget model, not a promise.
Regulatory Shifts: What Decree No. 818 Changes
The reason this is a complicated story is regulation. The source notes that China has been implementing new rules to support biomedical innovation and get new treatments to patients. Among them is State Council Decree No. 818, which took effect in May. According to the source, it sets out how new biomedical technologies can be brought into clinical use and creates an alternative pathway for eligible treatments. In principle, that could speed development and market entry.
Here's where it gets interesting. "Alternative pathway" doesn't mean "easier pathway." Eligibility criteria, the classes of products covered, and the evidence expected will determine whether a given programme qualifies. Before you build a China timeline around any new pathway, read the official decree text and get local regulatory counsel to confirm how it applies to your product class. Summaries, including this one, can miss conditions that matter.
Enterprise Singapore (ESG) is working on this front. Kow Juan Tiang, ESG's executive director for China, says the agency works with government officials and clinical research organisations to track regulatory changes, then shares that information with Singapore firms so they understand the rules they're operating under.
Where Singapore Firms Get Caught Out
Most guides frame China expansion as a speed play. The counter-intuitive point is that the firms benefiting most are usually the ones that treat regulation as a design input, not a hurdle to clear later.
Consider the sequence. A company that finishes early Singapore work, then discovers in month eight that its trial design doesn't match local expectations, loses the time it thought it had saved. The fix is to bring the regulatory question forward: map the pathway, identify which data China will accept from earlier Singapore trials, and decide early what needs to be re-run locally.
A common misconception is that "China is faster" is a universal truth. The source supports something narrower. Lion TCR and BetaLife describe gains from specific things: hospital partnerships, co-located manufacturing, and streamlined site preparation. If your bottleneck is somewhere else, such as a complex manufacturing process that doesn't transfer well, the advantage may shrink.
The other risk is partnership quality. Hospital collaborations are only as good as the people running them. Confirm who owns the data, who signs off on protocol amendments, and who is accountable when enrolment slows.
What to Do If You're Planning a China Expansion
If you're a founder or R&D lead weighing this move, the sequence matters more than the headline numbers.
- Map the regulatory pathway first. Identify whether your product falls under the new alternative route in Decree No. 818 and what evidence it requires.
- Model costs against your own study design. Use BetaLife's 20 to 50 percent figure as a range to test, not a conclusion.
- Secure clinical partners before you need them. A hospital that's willing to host a trial today is worth more than one you'll approach in six months.
- Decide what manufacturing stays where. Lion TCR's off-the-shelf work shows why cross-border production questions need answers early.
Pick one of these and act on it this week: pull the official text of Decree No. 818 and flag the two clauses that touch your product. Then book a call with Enterprise Singapore's China team, which the source says works with firms on exactly these questions.
Frequently Asked Questions
What is State Council Decree No. 818?
State Council Decree No. 818 is a Chinese regulation that took effect in May and sets out how new biomedical technologies can be brought into clinical use. According to CNA, it also creates an alternative pathway for eligible treatments that could speed up development and market entry. Eligibility depends on the product, so check the official decree text before planning around it.
How do Singapore biomedical startups start clinical trials in China?
Most start by building partnerships with local hospitals and research institutions, then mapping the regulatory pathway with help from advisers. Enterprise Singapore works with firms to track rule changes. Companies like BetaLife have set up local labs and partnered with hospitals such as the First Affiliated Hospital of Xiamen University before first-in-human studies.
Why do Singapore biomedical startups expand into China?
They're drawn by China's large patient population, including about 148 million adults with diabetes, along with hospital networks and manufacturing capacity. Lion TCR says its China setup has cut development time by roughly half, though that's a company estimate. The expansion is less about one advantage than about reducing the distance between research, clinical testing, and production.
Are clinical trials in China cheaper than in Singapore?
BetaLife estimates that a small-scale first-in-human cell therapy study in China could cost 20 to 50 percent less than an equivalent programme in Singapore. That's a company projection that depends on study design and site selection. Build your own budget model before relying on the range.
Singapore biomedical startups aren't moving to China because it's easy. They're moving because a larger patient base, closer hospital partnerships, and local manufacturing can shorten the path to a treatment. Pick the one regulatory question that most affects your product, answer it this week, and share this with a founder who's stuck trying to recruit enough patients at home.